{"id":"W4390372702","doi":"10.1016/j.jtho.2023.12.023","title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Eisai","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Placebo; Adverse effect; Oncology; Randomized controlled trial; Nivolumab; Gastroenterology; Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00146948,0.001846291,0.002992035,0.000481261,0.0004963869,0.001229787,0.0009577564,0.001628982,0.0061229],"category_scores_gemma":[0.0008691074,0.0006930719,0.001686872,0.0004213566,0.001220233,0.001544189,0.0003837934,0.003879033,0.001509176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009167644,"about_ca_system_score_gemma":0.001126427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001040685,"about_ca_topic_score_gemma":0.002613078,"domain_scores_codex":[0.9996153,0.0001511068,0.00001877004,0.00009218006,0.00003165603,0.00009088936],"domain_scores_gemma":[0.9996632,0.00008545777,0.0000557181,0.00002585855,0.00002166654,0.0001480278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9501716,0.007920071,0.0005479562,0.0009816134,0.00134706,0.0000526746,0.00006134212,0.0006871656,0.004784339,0.0002353022,0.00169947,0.03151126],"study_design_scores_gemma":[0.9528787,0.04428167,0.00090569,0.0000265794,0.0003335572,0.00002903871,0.00001685488,0.0004512475,0.0003513358,0.0001426816,0.0005700581,0.00001270266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802637,0.006732464,0.001090175,0.001025037,0.000907628,0.004760563,0.001385939,0.0002889842,0.003545701],"genre_scores_gemma":[0.98208,0.003943277,0.001632886,0.001502992,0.0003759161,0.004151761,0.001363756,0.00004235388,0.004907148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0061229,"threshold_uncertainty_score":0.02048308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09940783536830322,"score_gpt":0.4412411812161992,"score_spread":0.341833345847896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}